Complete response with sorafenib after immune-induced hepatitis with atezolizumab/bevacizumab for advanced hepatocellular carcinoma, synergic effect? - 07/11/23
Keywords : Hepatocellular carcinoma, Atezolizumab-Bevacizumab, Sorafenib, Immune-induced hepatitis
Mappa
☆ | Financial support: None. |
Acknowledgement: None. |
|
Manon Allaire is acting as the submission's guarantor. |
|
All authors approved the final version of the manuscript. |
|
Author contributions: Drs. Allaire, Araujo-Goncalves, Charlotte, Couty, Evain and Galy-Fauroux had full access to all data in the study and take responsibility for the integrity of data and the accuracy of data analysis. Study concept and design: Drs. Allaire and Evain. Acquisition of data: Drs. Allaire, Araujo-Goncalves, Charlotte, Evain and Galy-Fauroux. Analysis and interpretation of data: Drs. Allaire, Araujo-Goncalves, Charlotte, Couty, Evain and Galy-Fauroux. Drafting of the manuscript: Drs. Allaire, and Evain. Critical revision of the manuscript for important intellectual content: Drs. Allaire, Araujo-Goncalves, Charlotte, Couty, Evain and Galy-Fauroux. Statistical analysis: Dr Allaire. Study supervision: Drs Allaire and Couty. |
Vol 47 - N° 9
Articolo 102210- Novembre 2023 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?